ATE352614T1 - Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE352614T1
ATE352614T1 AT97950993T AT97950993T ATE352614T1 AT E352614 T1 ATE352614 T1 AT E352614T1 AT 97950993 T AT97950993 T AT 97950993T AT 97950993 T AT97950993 T AT 97950993T AT E352614 T1 ATE352614 T1 AT E352614T1
Authority
AT
Austria
Prior art keywords
ache
nuclease resistant
odn
production
selectively modulating
Prior art date
Application number
AT97950993T
Other languages
English (en)
Inventor
Hermona Soreq
Shlomo Seidman
Fritz Eckstein
Alon Friedman
Daniela Kaufer
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/850,347 external-priority patent/US6110742A/en
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE352614T1 publication Critical patent/ATE352614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97950993T 1996-12-12 1997-12-12 Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen ATE352614T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3526696P 1996-12-12 1996-12-12
US3777797P 1997-02-13 1997-02-13
US08/850,347 US6110742A (en) 1992-04-15 1997-05-02 Synthetic antisense oligodeoxynucleotides targeted to AChE
US5333497P 1997-07-21 1997-07-21

Publications (1)

Publication Number Publication Date
ATE352614T1 true ATE352614T1 (de) 2007-02-15

Family

ID=27488284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950993T ATE352614T1 (de) 1996-12-12 1997-12-12 Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen

Country Status (9)

Country Link
US (1) US6121046A (de)
EP (1) EP0951536B1 (de)
JP (1) JP4427639B2 (de)
AT (1) ATE352614T1 (de)
AU (1) AU727611B2 (de)
CA (1) CA2274985C (de)
DE (1) DE69737296T2 (de)
IL (1) IL130162A (de)
WO (1) WO1998026062A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475998B1 (en) * 1997-03-06 2002-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for the treatment of injury to the central nervous system
IL132972A0 (en) * 1999-11-16 2001-03-19 Yissum Res Dev Co Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
US20030060487A1 (en) * 2000-04-12 2003-03-27 Bamdad R. Shoshana Treatment of neurodegenerative disease
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
IL143379A (en) 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
IL158600A (en) 2003-10-26 2015-07-30 Hermona Soreq Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
CN1611509B (zh) * 2003-10-31 2010-04-28 中国人民解放军军事医学科学院毒物药物研究所 特异性识别人脑乙酰胆碱酯酶的核酸适配体及其用途
CN110384712B (zh) * 2019-07-16 2022-03-04 南方医科大学 核酸适配子在制备治疗阿尔茨海默氏病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
WO1994021294A1 (en) * 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
US5455044A (en) * 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
US5932780A (en) * 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances

Also Published As

Publication number Publication date
WO1998026062A2 (en) 1998-06-18
IL130162A (en) 2008-03-20
CA2274985A1 (en) 1998-06-18
CA2274985C (en) 2010-08-24
IL130162A0 (en) 2000-06-01
JP4427639B2 (ja) 2010-03-10
US6121046A (en) 2000-09-19
AU5385698A (en) 1998-07-03
DE69737296D1 (de) 2007-03-15
EP0951536B1 (de) 2007-01-24
JP2001510336A (ja) 2001-07-31
DE69737296T2 (de) 2007-11-08
AU727611B2 (en) 2000-12-14
EP0951536A1 (de) 1999-10-27
WO1998026062A3 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
PT928335E (pt) Metodo de utilizacao de oligonucleotidos contendo dinucleosidos cpg modificados
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
MX9603489A (es) Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB9417532D0 (en) Aromatic compounds
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
BG100830A (en) Naphthylamides as central nervous system agents
CA2210998A1 (en) Inhibition of neovascularization using vegf-specific oligonucleotides
ATE352614T1 (de) Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
TR200000149T2 (tr) Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar
CA2373757A1 (en) Treatment of neurotic disorders
ES2159647T3 (es) Factor neurotrofico derivado de neurogliocitos como agente neuroprotector.
Latha et al. Efficacy of yoga therapy in the management of headaches.
IL132972A0 (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
ATE242200T1 (de) Valnoctamid-stereoisomere, eine methode zu ihrer herstellung und abtrennung und ihre anwendungen
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE69727222D1 (de) Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten
BR0016720A (pt) Uso de trimebutina para tratamento de dores
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
UA29910A (uk) Спосіб лікування дисфункції скоренево- нижньощелепного суглоба
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
MX9801192A (es) Nuevos peptidos opioides.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties